373 related articles for article (PubMed ID: 30414782)
1. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial.
Macias Parra M; Gentile A; Vazquez Narvaez JA; Capdevila A; Minguez A; Carrascal M; Willemsen A; Bhusal C; Toneatto D
Vaccine; 2018 Nov; 36(50):7609-7617. PubMed ID: 30414782
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study.
Dbaibo G; Tinoco Favila JC; Traskine M; Jastorff A; Van der Wielen M
Vaccine; 2018 Jun; 36(28):4102-4111. PubMed ID: 29784470
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults.
Beran J; Dražan D; Enweonye I; Bhusal C; Toneatto D
mSphere; 2021 Dec; 6(6):e0055321. PubMed ID: 34787449
[TBL] [Abstract][Full Text] [Related]
4. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM
Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906
[TBL] [Abstract][Full Text] [Related]
5. Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods.
Klein NP; Block SL; Essink B; Barbi S; Smolenov I; Keshavan P
Vaccine; 2019 Jul; 37(32):4460-4467. PubMed ID: 31279564
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults.
Alberer M; Burchard G; Jelinek T; Reisinger EC; Meyer S; Forleo-Neto E; Dagnew AF; Arora AK
J Travel Med; 2015; 22(2):105-14. PubMed ID: 25483566
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: A phase 3b, randomized controlled trial.
P Safadi MA; Martinon-Torres F; Weckx LY; Moreira ED; da Fonseca Lima EJ; Mensi I; Calabresi M; Toneatto D
Vaccine; 2017 Apr; 35(16):2052-2059. PubMed ID: 28318767
[TBL] [Abstract][Full Text] [Related]
8. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.
Block SL; Szenborn L; Daly W; Jackowska T; D'Agostino D; Han L; Dull PM; Smolenov I
Vaccine; 2015 May; 33(21):2500-10. PubMed ID: 25795256
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.
Saez-Llorens X; Aguilera Vaca DC; Abarca K; Maho E; Graña MG; Heijnen E; Smolenov I; Dull PM
Hum Vaccin Immunother; 2015; 11(6):1507-17. PubMed ID: 25969894
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates.
Kimura A; Toneatto D; Kleinschmidt A; Wang H; Dull P
Clin Vaccine Immunol; 2011 Mar; 18(3):483-6. PubMed ID: 21177912
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
[TBL] [Abstract][Full Text] [Related]
13. Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized Study.
Szenborn L; Block SL; Jackowska T; Konior R; D'Agostino D; Smolenov I; Toneatto D; Welsch JA
Pediatr Infect Dis J; 2018 May; 37(5):475-482. PubMed ID: 29329168
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
Peterson J; Drazan D; Czajka H; Maguire J; Pregaldien JL; Seppa I; Maansson R; O'Neill R; Balmer P; Jodar L; Jansen KU; Anderson AS; Perez JL; Beeslaar J
Lancet Infect Dis; 2023 Dec; 23(12):1370-1382. PubMed ID: 37579773
[TBL] [Abstract][Full Text] [Related]
16. MenACWY-CRM conjugate vaccine booster dose given 4-6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults.
Tipton M; Daly W; Senders S; Block SL; Lattanzi M; Mzolo T; Barbi S; Pellegrini M; Keshavan P
Vaccine; 2019 Sep; 37(42):6171-6179. PubMed ID: 31495595
[TBL] [Abstract][Full Text] [Related]
17. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
Rivera L; Schwarz TF; Kim KH; Kim YK; Behre U; Cha SH; Jo DS; Lee J; Lee JS; Cheuvart B; Jastorff A; Van der Wielen M
Vaccine; 2018 Jul; 36(31):4750-4758. PubMed ID: 29960800
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
[TBL] [Abstract][Full Text] [Related]
20. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM;
Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
